
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is a provider of genomic sequencing and analytics solutions for personalized cancer vaccines, with its latest acquisition by Tempus AI Inc implying an overall transaction value of $1.7B. With a potential for Medicare coverage and strong financials, Personalis is on track to meet its 2026 guide for $78-80M in revenue and Gross Margin of 15-20%.
Bears say
Personalis is currently facing several fundamental challenges that are likely to hinder its financial performance in the future. These challenges include a high cash burn rate, negative operating margin, and significant competition in its core markets, resulting in lower-than-expected revenues. Additionally, the company's reliance on a single segment for its revenues and a potential discount in its valuation compared to its peers contribute to our negative outlook on Personalis's stock. All of these factors combined make us believe that investing in this stock may not be a profitable venture.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares